Home
About
FAQ
History (5)
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Dopamine
Frullania
Motor Activity
Retinal Vein Occlusion
See All 5 Pages
Find People
Find Everything
Edit My Profile
My Person List (
0
)
Return to Top
Login
Username
Password